Who are Ivermectin 0.1% Metronidazole 1%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pyrimethamine plus Sulfadiazine plus leucoverin, Pyrimethamine/Sulfadiazine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ivermectin-0-1-metronidazole-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ivermectin 0.1% Metronidazole 1% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ivermectin 0.1% Metronidazole 1% (Ivermectin 0.1% Metronidazole 1%) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiparasitic/Antimicrobial combination. Area: Infectious Disease / Dermatology.

phase 3 Antiparasitic/Antimicrobial combination Glutamate-gated chloride channels (ivermectin); DNA/anaerobic metabolism (metronidazole) Infectious Disease / Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Ivermectin 0.1% Metronidazole 1% (Ivermectin 0.1% Metronidazole 1%) — Universidad Nacional de Colombia. This combination product uses ivermectin to paralyze parasites and metronidazole to disrupt microbial DNA, targeting parasitic and anaerobic bacterial infections.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ivermectin 0.1% Metronidazole 1% TARGET	Ivermectin 0.1% Metronidazole 1%	Universidad Nacional de Colombia	phase 3	Antiparasitic/Antimicrobial combination	Glutamate-gated chloride channels (ivermectin); DNA/anaerobic metabolism (metronidazole)
Pyrimethamine plus Sulfadiazine plus leucoverin	Pyrimethamine plus Sulfadiazine plus leucoverin	Department of Medical Services Ministry of Public Health of Thailand	marketed	Antiparasitic/antimicrobial combination	Dihydrofolate reductase (parasitic and bacterial)
Pyrimethamine/Sulfadiazine	Pyrimethamine/Sulfadiazine	Assistance Publique - Hôpitaux de Paris	phase 3	Antiparasitic/Antimicrobial combination	Dihydrofolate reductase (pyrimethamine); Dihydropteroate synthase (sulfadiazine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiparasitic/Antimicrobial combination class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Universidad Nacional de Colombia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ivermectin 0.1% Metronidazole 1% — Competitive Intelligence Brief. https://druglandscape.com/ci/ivermectin-0-1-metronidazole-1. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab